Autism Clinical Studies

Children’s Autism Metabolome Project (CAMP) I

Identification of Amino Acid Dysregulation Subtypes

Our CAMP I study is the largest clinical study to date to evaluate the metabolism of children with autism spectrum disorder (ASD). It was funded by a research grant on autism from the National Institutes of Mental Health (NIMH). The details and results of this clinical study were first published in a paper in the scientific journal of Biological Psychiatry and, subsequently, a paper in Autism Research. This research was informed by our three earlier autism studies, which also investigated the connection between metabolism and autism.

  • Validated our NeuroPointDX autism spectrum disorder (NPDX ASD) blood test which may lead to an earlier ASD diagnosis for some children
  • Compared a child’s comprehensive metabolic panel blood plasma sample results to their behavioral evaluation to identify differences in metabolism of children who were diagnosed with ASD
  • Conducted at 8 clinical study sites, including some of the leading autism centers in the country
  • Enrolled 1,100 children aged 18-48 months old

CAMP I Clinical Sites

This study was funded by a grant from the National Institutes of Mental Health and investments by the Nancy Lurie Marks Family Foundation and the Robert E. and Donna Landreth Family Fund. We are grateful to all of the children and families who participated in the CAMP I clinical study who helped us better understand ASD and develop the NeuroPointDX autism spectrum disorder (NPDX ASD) blood test.

UC-Davis MIND Institute
Dr. David Amaral – Principal Investigator

Nationwide Children’s Hospital
Dr. Daniel Coury – Principal Investigator

Massachusetts General Hospital
Lurie Center for Autism
Dr. Ann Neumeyer – Principal Investigator

Melmed Center
Dr. Raun Melmed – Principal Investigator

Monroe Carell, Jr. Children’s Hospital at Vanderbilt
Dr. Kevin Sanders – Principal Investigator
Dr. Allyson Cundiff – Principal Investigator

Children’s Hospital of Philadelphia (CHOP)
Dr. Amanda Bennett-Palladino – Principal Investigator

Arkansas Children’s Research Hospital
Dr. Richard Frye – Principal Investigator
(no longer at Arkansas Children’s Research Hospital)

Cincinnati Children’s Hospital Medical Center
Dr. Logan Wink – Principal Investigator
(no longer at Cincinnati Children’s Hospital)

Support our next clinical trial, CAMP II: Branched Chain Amino Acids (BCAA) Dysregulation Subtype Study.

We strive to improve the lives of children and families living with autism spectrum disorder and other neurological disorders by providing tools for earlier diagnosis and more precise treatment.